Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$1.16B+216.73%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jan van de Winkel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,119
- Beta
- 0.70
- Country
- DK
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 14.34
Financials
Revenue
$1.16B+216.7%Net Income
$303.00M+60.4%EBITDA
$431.00M+121.3%Free Cash Flow
$48.00M-76.4%EPS (diluted)
$0.49+58.1%Shares Outstanding (diluted)
617.11M-0.1%Operating Expenses
$664.00MCash & Debt
$1.50BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.72B | $963.76M | $1.55 |
| 2024 | $21.53B | $7.84B | $12.14 |
| 2023 | $16.47B | $4.35B | $6.60 |
| 2022 | $14.51B | $5.45B | $8.34 |
| 2021 | $8.42B | $2.96B | $4.52 |
| 2020 | $10.11B | $4.76B | $7.30 |
| 2019 | $5.37B | $2.17B | $3.44 |
| 2018 | $3.03B | $1.47B | $2.40 |
| 2017 | $2.37B | $1.10B | $1.81 |
| 2016 | $1.82B | $1.19B | $1.98 |
| 2015 | $1.13B | $763.51M | $1.31 |
| 2014 | $850.38M | $301.30M | $0.54 |
| 2013 | $663.57M | $112.36M | $0.22 |
| 2012 | $484.64M | $-487.12M | $-1.06 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.28
- Implied price
- $45.57
- Return from $37.80
- 3.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.66 — -40.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.0% | -12.3% | -8.8% | -5.8% | -3.1% | -0.7% |
| 3.0% | -7.8% | -4.2% | -1.0% | 1.8% | 4.3% |
| 8.0% | -3.3% | 0.5% | 3.8% | 6.8% | 9.4% |
| 13.0% | 1.1% | 5.1% | 8.6% | 11.7% | 14.5% |
| 18.0% | 5.6% | 9.8% | 13.4% | 16.6% | 19.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
139+177.78%Social Signal Score
Mentions (11)
- Newsseekingalpha.com·3d ago·Neutral
Genmab: Epkinly Shines In Phase 3 DLBCL Trial Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.
View source ↗ - Newszacks.com·3d ago·Neutral
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
View source ↗ - Newswsj.com·3d ago·Negative
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.
View source ↗ - Newsglobenewswire.com·4d ago·Negative
…iagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and…
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…ROC) Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression and non-expressors Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), R…
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company's vice president and head of investor relations.
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Genmab to Participate in Upcoming Investor Conferences Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026 :
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.37 per share
Typical surprise +35.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.54 vs $0.37beat
- Thu, May 7$0.09 vs $0.15miss
- Tue, Feb 17$0.05 vs $0.46miss
- Thu, Nov 6$0.65 vs $0.48beat
- Thu, Aug 7$0.54 vs $0.39beat
- Thu, May 8$0.31 vs $0.23beat
Estimates and results for GMAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 11, 2025 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 14, 2025 (29d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (27d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (33d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (32d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (178d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 2, 2020 (12d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.